Bioventus Inc. (BVS) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Bioventus reported revenue of $568.1M, down 0.9% from $573.3M the year before. Net income was $22.7M (a 4.0% net margin), or $0.33 per diluted share. Gross margin was 68.3% and operating margin was 9.5%. Operating activities generated $74.7M of cash, leaving $72.1M of free cash flow. At fiscal year end, Bioventus held $683.6M in total assets against $455.1M in total liabilities, including $51.2M of cash and equivalents.
Open the full interactive Bioventus financials → Quarterly statements, key ratios, valuation history and price charts.
Bioventus Key Stats
| Share Price | $13.56 |
|---|---|
| Market Cap | $960.6M |
| P/E Ratio | 41.1 |
| Revenue YoY Growth | -0.9% |
| 52-Week Range | $6.53 – $15.26 |
| Shares Outstanding | 67.9 million (basic, 2026 Q2) |
Bioventus Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $430.9M | $512.1M | $512.3M | $573.3M | $568.1M |
| Cost of Goods Sold | $128.2M | $181.0M | $184.2M | $185.1M | $179.9M |
| Gross Profit | $302.7M | $331.1M | $328.2M | $388.2M | $388.2M |
| Operating Income | $12.1M | -$251.0M | -$81.7M | -$12.0M | $54.0M |
| Pre-Tax Income | $7.6M | -$263.9M | -$121.1M | -$49.1M | $25.7M |
| Income Tax | -$2.0M | -$50.5M | $85,000 | -$5.3M | -$1.6M |
| Net Income | $19.4M | -$158.7M | -$156.2M | -$33.5M | $22.7M |
| Diluted EPS | -$0.15 | -$2.59 | -$2.49 | -$0.52 | $0.33 |
Bioventus Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $138.7M | $157.9M | $132.1M | $153.2M |
| Net Income | $3.2M | $14.8M | $3.1M | $33.4M |
| Diluted EPS | $0.05 | $0.21 | $0.04 | $0.47 |
Bioventus Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $43.9M | $31.8M | $37.0M | $41.6M | $51.2M |
| Current Assets | $263.1M | $272.6M | $268.0M | $275.6M | $272.8M |
| Total Assets | $1.23B | $1.37B | $810.9M | $728.0M | $683.6M |
| Current Liabilities | $180.9M | $304.0M | $175.5M | $210.4M | $160.4M |
| Total Long-Term Debt | $357.7M | $418.1M | $394.8M | $335.6M | $294.0M |
| Total Liabilities | $692.1M | $1.03B | $589.8M | $542.4M | $455.1M |
| Shareholders' Equity | $458.9M | $316.6M | $173.6M | $147.9M | $184.1M |
Bioventus Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | $23.0M | -$13.5M | $15.3M | $38.8M | $74.7M |
| Cash From Investing | -$283.8M | -$116.4M | $15.8M | $23.0M | -$3.2M |
| Cash From Financing | $273.4M | $62.1M | -$26.7M | -$54.6M | -$62.1M |
| Free Cash Flow | $15.6M | -$23.6M | $8.0M | $37.8M | $72.1M |
Figures from Bioventus' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Bioventus financials page for every line item.
Bioventus Company Profile
| Ticker | BVS |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Durham, North Carolina |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer, emerging growth company |
| SEC CIK | 0001665988 |
Frequently Asked Questions
What was Bioventus' revenue in fiscal 2025?
Bioventus (BVS) reported revenue of $568.1M for fiscal 2025.
What is Bioventus' annual revenue history?
Bioventus' annual revenue by fiscal year: 2021: $430.9M; 2022: $512.1M; 2023: $512.3M; 2024: $573.3M; 2025: $568.1M.
What was Bioventus' net income in fiscal 2025?
Bioventus reported net income of $22.7M for fiscal 2025.
What was Bioventus' earnings per share (EPS) in fiscal 2025?
Bioventus' diluted EPS was $0.33 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Bioventus generate in fiscal 2025?
Bioventus generated $72.1M of free cash flow in fiscal 2025.
What was Bioventus' revenue last quarter?
In its most recent reported quarter (2026 Q2), Bioventus reported revenue of $153.2M.
How much debt does Bioventus have?
Bioventus reported $294.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Bioventus are outstanding?
Bioventus reported a weighted average of 67.9 million basic shares outstanding in 2026 Q2.
What is Bioventus' market cap?
Based on its latest closing price, Bioventus (BVS) has a market capitalization of about $960.6M.
When does Bioventus' fiscal year end?
Bioventus' fiscal year end, as registered with the SEC, is December 31.
Where is Bioventus headquartered?
Bioventus lists its business address in Durham, North Carolina in its SEC filings.